Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Angelika Mehnert

Showing results (1-10 of 12) with videos related to

Pageof 2
Sort By:
Journal of Clinical Psychopharmacology|May 17, 2006
To what extent do the PANSS and CGI-S overlap?Jonathan Rabinowitz, Angelika Mehnert, Marielle Eerdekens
Zeitschrift Fur Evidenz, Fortbildung Und Qualitat Im Gesundheitswesen|July 9, 2010
[Objectivity in research in the pharmaceutical industry is possible]Koen Torfs, Ina Rudolph, Angelika Mehnert, et al.
Journal of Medical Economics|March 31, 2012
Cost effectiveness of paliperidone palmitate versus risperidone long-acting injectable and olanzapine pamoate for the treatment of patients with schizophrenia in SwedenAngelika Mehnert, Deborah Nicholl, Hanna Pudas, et al.
Pharmacoeconomics|January 19, 2006
Costs and effects of long-acting risperidone compared with oral atypical and conventional depot formulations in GermanyGerd Laux, Bart Heeg, Ben A van Hout, et al.
The Journal of Clinical Psychiatry|May 4, 2004
Health-related quality of life in patients with schizophrenia during treatment with long-acting, injectable risperidoneHenry A Nasrallah, Inge Duchesne, Angelika Mehnert, et al.
Current Medical Research and Opinion|October 13, 2015
Indirect comparison of the antiviral efficacy of peginterferon alpha 2a plus ribavirin used with or without simeprevir in genotype 4 hepatitis C virus infection, where common comparator study arms are lacking: a special application of the matching adjusted indirect comparison methodologySuzy Van Sanden, Marta Pisini, Inge Duchesne, et al.
Dementia and Geriatric Cognitive Disorders|July 30, 2002
Economic analysis of galantamine, a cholinesterase inhibitor, in the treatment of patients with mild to moderate Alzheimer's disease in the NetherlandsJ Jaime Caro, Maribel Salas, Alexandra Ward, et al.
The British Journal of Psychiatry : the Journal of Mental Science|August 2, 2005
Perceived functioning, well-being and psychiatric symptoms in patients with stable schizophrenia treated with long-acting risperidone for 1 yearW Wolfgang Fleischhacker, Jonathan Rabinowitz, Georg Kemmler, et al.
Journal of Medical Economics|April 24, 2015
A cost utility analysis of simeprevir used with peginterferon + ribavirin in the management of genotype 1 hepatitis C virus infection, from the perspective of the UK National Health ServiceKirsten Westerhout, Maarten Treur, Angelika Mehnert, et al.
International Clinical Psychopharmacology|June 4, 2005
Minimal injection site pain and high patient satisfaction during treatment with long-acting risperidoneJean-Pierre Lindenmayer, Kathleen Jarboe, Cynthia A Bossie, et al.
Pageof 2

Showing results (1-10 of 12) with videos related to

Sort By:
Pageof 2
Journal of Clinical Psychopharmacology|May 17, 2006
To what extent do the PANSS and CGI-S overlap?Jonathan Rabinowitz, Angelika Mehnert, Marielle Eerdekens
Zeitschrift Fur Evidenz, Fortbildung Und Qualitat Im Gesundheitswesen|July 9, 2010
[Objectivity in research in the pharmaceutical industry is possible]Koen Torfs, Ina Rudolph, Angelika Mehnert, et al.
Journal of Medical Economics|March 31, 2012
Cost effectiveness of paliperidone palmitate versus risperidone long-acting injectable and olanzapine pamoate for the treatment of patients with schizophrenia in SwedenAngelika Mehnert, Deborah Nicholl, Hanna Pudas, et al.
Pharmacoeconomics|January 19, 2006
Costs and effects of long-acting risperidone compared with oral atypical and conventional depot formulations in GermanyGerd Laux, Bart Heeg, Ben A van Hout, et al.
The Journal of Clinical Psychiatry|May 4, 2004
Health-related quality of life in patients with schizophrenia during treatment with long-acting, injectable risperidoneHenry A Nasrallah, Inge Duchesne, Angelika Mehnert, et al.
Current Medical Research and Opinion|October 13, 2015
Indirect comparison of the antiviral efficacy of peginterferon alpha 2a plus ribavirin used with or without simeprevir in genotype 4 hepatitis C virus infection, where common comparator study arms are lacking: a special application of the matching adjusted indirect comparison methodologySuzy Van Sanden, Marta Pisini, Inge Duchesne, et al.
Dementia and Geriatric Cognitive Disorders|July 30, 2002
Economic analysis of galantamine, a cholinesterase inhibitor, in the treatment of patients with mild to moderate Alzheimer's disease in the NetherlandsJ Jaime Caro, Maribel Salas, Alexandra Ward, et al.
The British Journal of Psychiatry : the Journal of Mental Science|August 2, 2005
Perceived functioning, well-being and psychiatric symptoms in patients with stable schizophrenia treated with long-acting risperidone for 1 yearW Wolfgang Fleischhacker, Jonathan Rabinowitz, Georg Kemmler, et al.
Journal of Medical Economics|April 24, 2015
A cost utility analysis of simeprevir used with peginterferon + ribavirin in the management of genotype 1 hepatitis C virus infection, from the perspective of the UK National Health ServiceKirsten Westerhout, Maarten Treur, Angelika Mehnert, et al.
International Clinical Psychopharmacology|June 4, 2005
Minimal injection site pain and high patient satisfaction during treatment with long-acting risperidoneJean-Pierre Lindenmayer, Kathleen Jarboe, Cynthia A Bossie, et al.
Pageof 2